Clinical Trial Update: Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating empagliflozin as adjuvant therapy for ulcerative colitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Sadat City University | Conditions: Ulcerative Colitis | Phase 2 | Status: WITHDRAWN